Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants.
Kokas Z, Járdánházy A, Sandi D, Biernacki T, Fricska-Nagy Z, Füvesi J, Bartosik-Psujek H, Kes VB, Berger T, Berthele A, Drulovic J, Hemmer B, Horakova D, Ledinek AH, Havrdova EK, Magyari M, Rejdak K, Tiu C, Turcani P, Klivényi P, Kincses ZT, Vécsei L, Bencsik K. Kokas Z, et al. Among authors: havrdova ek. Mult Scler Relat Disord. 2023 Jan;69:104406. doi: 10.1016/j.msard.2022.104406. Epub 2022 Nov 8. Mult Scler Relat Disord. 2023. PMID: 36413917 Review.
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event.
Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Ramanathan M. Horakova D, et al. J Neuroimmunol. 2011 Jul;236(1-2):76-80. doi: 10.1016/j.jneuroim.2011.04.011. Epub 2011 May 31. J Neuroimmunol. 2011. PMID: 21621859 Clinical Trial.
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Panayiotou P, Jazbec SS, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Havrdová E. Fazekas F, et al. Wien Med Wochenschr. 2012 Aug;162(15-16):354-66. doi: 10.1007/s10354-012-0123-y. Epub 2012 Aug 16. Wien Med Wochenschr. 2012. PMID: 22895849 Free PMC article. Review.
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, Fabjan TH, Fazekas F, Fuchs S, Havrdova E, Ledinek AH, Illes Z, Jazbec SS, Klimova E, Komoly S, Kurca E, Linnebank M, Lisy L, Mares J, Prochazkova L, Csilla R, Szilasiova J, Stourac P, Talab R, Turcani P, Vachova M, Vecsei L, Vodusek D, Zapletalova O, Berger T. Preiningerova JL, et al. CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101. CNS Neurosci Ther. 2013. PMID: 23607697 Free PMC article.
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kobys T, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Nehrych T, Moskovko S, Panayiotou P, Jazbec SŠ, Sokolova L, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Voloshyná N, Havrdová E. Fazekas F, et al. Front Neurol. 2013 May 1;4:10. doi: 10.3389/fneur.2013.00010. eCollection 2013. Front Neurol. 2013. PMID: 23641231 Free PMC article.
210 results